Co-Diagnostics
Co-Diagnostics
CODX
NASDAQ
0.46
USD
-4.17%
About
Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease.
Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use.
The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 976.6K |
| Three Month Average Volume | 6.1M |
| High Low | |
| Fifty-Two Week High | 2.2299 USD |
| Fifty-Two Week Low | 0.9811 USD |
| Fifty-Two Week High Date | 23 Aug 2024 |
| Fifty-Two Week Low Date | 04 Oct 2023 |
| Price and Volume | |
| Current Price | 1.39 USD |
| Beta | -1 |
| Relative Price Change | |
| Four Week Relative Price Change | 20.71% |
| Thirteen Week Relative Price Change | 23.69% |
| Twenty-Six Week Relative Price Change | 8.98% |
| Fifty-Two Week Relative Price Change | -10.54% |
| Year-to-Date Relative Price Change | -11.74% |
| Price Change | |
| One Day Price Change | -2.11% |
| Thirteen Week Price Change | 32.38% |
| Twenty-Six Week Price Change | 19.83% |
| Five Day Price Change | -20.57% |
| Fifty-Two Week Price Change | 12.10% |
| Year-to-Date Price Change | 4.51% |
| Month-to-Date Price Change | 20.87% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 2.75158 USD |
| Book Value Per Share (Most Recent Quarter) | 2.26874 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 1.90693 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 1.44606 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -1.26006 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.23212 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.30765 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1.20399 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -1.26611 USD |
| Normalized (Last Fiscal Year) | -1.22813 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.20399 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -1.26611 USD |
| Including Extraordinary Items (Last Fiscal Year) | -1.20399 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -1.26611 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 1.87297 USD |
| Cash Per Share (Most Recent Quarter) | 1.4064 USD |
| Cash Flow Per Share (Last Fiscal Year) | -1.16206 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -1.22199 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.88453 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | 21 |
| Cash Flow Revenue (Trailing Twelve Months) | -288 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -391.88% |
| Pretax Margin (Last Fiscal Year) | -559.46% |
| Pretax Margin (5 Year) | 11.72% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 38.57% |
| Gross Margin (Trailing Twelve Months) | 59.83% |
| Gross Margin (5 Year) | 82.24% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -610.88% |
| Operating Margin (Trailing Twelve Months) | -424.64% |
| Operating Margin (5 Year) | 9.91% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -518.68% |
| Net Profit Margin (Trailing Twelve Months) | -411.19% |
| Net Profit Margin (5 Year) | 10.94% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 1,243.13% |
| Revenue Growth (3 Year) | 179.54% |
| Revenue Change (Trailing Twelve Months) | 25.24% |
| Revenue Per Share Growth | 135.61% |
| Revenue Growth (5 Year) | -54.96% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 101.27% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 17.73% |
| EPS Change (Trailing Twelve Months) | 1.52% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 1 |
| Price to Tangible Book (Most Recent Quarter) | 1 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -44,879,680 |
| Net Debt (Last Fiscal Year) | -58,548,390 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 7 |
| Price to Sales (Trailing Twelve Months) | 5 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 74 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 5 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 1 |
| Price to Book (Most Recent Quarter) | 1 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 11 |
| Quick Ratio (Most Recent Quarter) | 9 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 11 |
| Current Ratio (Most Recent Quarter) | 9 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -23,447,180 |
| Free Cash Flow (Trailing Twelve Months) | -26,269,690 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -32.36% |
| Return on Assets (Trailing Twelve Months) | -38.83% |
| Return on Assets (5 Year) | 5.77% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -35.24% |
| Return on Equity (Trailing Twelve Months) | -42.73% |
| Return on Equity (5 Year) | 6.49% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -33.85% |
| Return on Investment (Trailing Twelve Months) | -41.04% |
| Return on Investment (5 Year) | 6.15% |